RTAC: FES/Cerianna Screening for Estrogen Positive MBC
Entities of Cancer, MBC Imaging and Profiling, Medical Community, Novel Treatments, Diagnosis and Treatment, MBC Patients, MBC Stories, Quality of Life Our MBClife Entities of Cancer, MBC Imaging and Profiling, Medical Community, Novel Treatments, Diagnosis and Treatment, MBC Patients, MBC Stories, Quality of Life Our MBClife

RTAC: FES/Cerianna Screening for Estrogen Positive MBC

There’s a FDA- approved diagnostic imaging agent developed to comprehensively evaluate estrogen receptor-positive (ER+) lesions in recurrent or metastatic breast cancer as an adjunct to biopsy. By creating a “whole-body” picture of ER+ lesions, Cerianna may be a helpful diagnostic tool in helping oncologists better determine the most appropriate course of treatment. Learn more in this episode.

Read More
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
Novel Treatments, Clinical Research, Medical Community, Entities of Cancer, Diagnosis and Treatment, Difficult to Treat, Updates from Conferences Our MBClife Novel Treatments, Clinical Research, Medical Community, Entities of Cancer, Diagnosis and Treatment, Difficult to Treat, Updates from Conferences Our MBClife

ASCO 2022: When the Dust Settles, Will ADCs Change MBC?

While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.

Read More
ER Progression and Resistance: Causes, Consequences, and Hope
Novel Treatments, Obstacles to Better Outcomes, Medical Community, Entities of Cancer, Difficult to Treat, Clinical Research, Precision Oncology, MBC Imaging and Profiling, Translational Research, Basic Science, Diagnosis and Treatment, Patient Reported Outcomes and Out of the Box Treatment Options Our MBClife Novel Treatments, Obstacles to Better Outcomes, Medical Community, Entities of Cancer, Difficult to Treat, Clinical Research, Precision Oncology, MBC Imaging and Profiling, Translational Research, Basic Science, Diagnosis and Treatment, Patient Reported Outcomes and Out of the Box Treatment Options Our MBClife

ER Progression and Resistance: Causes, Consequences, and Hope

Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.

Read More
Dr. Stephanie Graff: Understanding Progression
Essential Knowledge, Medical Community, Challenges and Barriers, MBC Imaging and Profiling, Difficult to Treat, Novel Treatments, Obstacles to Better Outcomes, Diagnosis and Treatment, Entities of Cancer Our MBClife Essential Knowledge, Medical Community, Challenges and Barriers, MBC Imaging and Profiling, Difficult to Treat, Novel Treatments, Obstacles to Better Outcomes, Diagnosis and Treatment, Entities of Cancer Our MBClife

Dr. Stephanie Graff: Understanding Progression

What does it mean when our cancer shows progression? And how do we know when that happens? The Our MBC Life team gets the lowdown from Dr. Stephanie L. Graff.

Read More